Kane Biotech Announces Attendance at Upcoming Wound Care Conferences
September 26, 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) announces that the Company will be showcasing its revyve™...
Kane Biotech Announces Exercise of Warrants
September 12, 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces the exercise of an aggregate of 5 million warrants at an...
Kane Biotech Announces Second Quarter 2024 Financial Results
August 29, 2024 16:15 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) today announces its second quarter 2024 financial results....
Kane Biotech Announces new DispersinB® Publication in Pathogens and Conference Presentations
August 29, 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces the publication of a new review article on DispersinB® in the...
Kane Biotech Announces Distribution Agreement with Qatar Datamation Systems for revyve™ Antimicrobial Wound Gel
August 28, 2024 08:40 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces that it has signed a three year distribution...
Kane Biotech to Release Second Quarter 2024 Financial Results on August 29, 2024 – Conference Call to Follow
August 22, 2024 16:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”) will announce its second quarter 2024 financial results after market close on...
Kane Biotech Announces Distribution Agreement with Razan Medical Trading for revyve™ Antimicrobial Wound Gel
August 22, 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announces that it has signed a three year distribution...
Kane Biotech Receives Funding Support to Expand the revyve™ Antimicrobial Wound Gel Family
August 13, 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) announces that it is receiving advisory services and up to...
Kane Biotech Receives FDA Approval to Increase Dosage Allowance of its revyve™ Antimicrobial Wound Gel
July 23, 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, July 23, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) announces that the US Food and Drug Administration (FDA)...
Kane Biotech Receives ISO 13485:2016 MDSAP Quality Certification
July 17, 2024 08:30 ET
|
Kane Biotech Inc.
WINNIPEG, Manitoba, July 17, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has received ISO 13485:2016 Medical Device Single Audit...